Patents by Inventor Wan-Jen Hong

Wan-Jen Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240091248
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 21, 2024
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • Publication number: 20230027184
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: September 15, 2022
    Publication date: January 26, 2023
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • Publication number: 20230000889
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: June 7, 2022
    Publication date: January 5, 2023
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • Publication number: 20220133794
    Abstract: Antigen binding domain polypeptides (ABD) specific for human CD93 are provided, which ABD may be formatted as antibodies, as chimeric antigen receptors, and the like. T cells comprising an anti-CD93 CAR are useful in the treatment of cancer, e.g. hematologic malignancies.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 5, 2022
    Inventors: Ravindra Majeti, Crystal Mackall, Jie Liu, Robbie Majzner, Rebecca Richards, Wan-Jen Hong
  • Patent number: 7465542
    Abstract: Methods are provided for determining whether a patient treated with an anti-proliferative agent is susceptible to toxicity. In practicing the subject methods, an expression profile for the transcriptional response to a therapy is obtained from the patient and compared to a reference profile to determine whether the patient is susceptible to toxicity. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: December 16, 2008
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gilbert Chu, Virginia G. Tusher, Jean Tang, Kerri Elyse Rieger, Wan-Jen Hong, Robert Tibshirani
  • Publication number: 20040152109
    Abstract: Methods are provided for determining whether a patient treated with an anti-proliferative agent is susceptible to toxicity. In practicing the subject methods, an expression profile for the transcriptional response to a therapy is obtained from the patient and compared to a reference profile to determine whether the patient is susceptible to toxicity. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.
    Type: Application
    Filed: October 14, 2003
    Publication date: August 5, 2004
    Inventors: Gilbert Chu, Virginia G. Tusher, Jean Tang, Kerri Elyse Rieger, Wan-Jen Hong, Robert Tibshirani